Barbier L, Vulto AG. Interchangeability of biosimilars: overcoming the final hurdles. Drugs. 2021;81:1897–903. https://doi.org/10.1007/s40265-021-01629-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther. 2022;22:133–48. https://doi.org/10.1080/14712598.2021.1889511.

Article  PubMed  Google Scholar 

Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020. https://doi.org/10.1007/s40259-020-00433-y.

Article  PubMed  PubMed Central  Google Scholar 

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36:1260–5. https://doi.org/10.1200/JCO.2017.77.4893.

Article  PubMed  Google Scholar 

Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81:1859–79. https://doi.org/10.1007/s40265-021-01610-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbier L, Mbuaki A, Simoens S, Vulto A, Huys I. The role of regulatory guidance and information dissemination for biosimilar medicines—the perspective of healthcare professionals and industry. 2019. https://www.ispor.org/docs/default-source/euro2019/20191011ispor-europe-regulatory-guidance-and-info-biosimilarslb-pdf.pdf?sfvrsn=81181f1e_0. Accessed on 12 Oct 2022

Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016. https://doi.org/10.1136/annrheumdis-2016-209166.

Article  PubMed  Google Scholar 

Patrikos D, Boki K, Boumpas D, Vassilopoulos D. Position paper on biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. Mediterr J Rheumatol. 2018;30:82–5. https://doi.org/10.31138/mjr.30.1.82.

Article  Google Scholar 

Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifoni MAC, Gil RA, et al. The use of biosimilar medicines in oncology—position statement of the Brazilian Society of Clinical Oncology (SBOC). Braz J Med Biol Res. 2018;51:1–7. https://doi.org/10.1590/1414-431X20177214.

Article  Google Scholar 

Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohns Colitis. 2017;11:26–34. https://doi.org/10.1093/ecco-jcc/jjw198.

Article  PubMed  Google Scholar 

Torres T, Ferreira A, Ferreira P, Henriques M, Leite L, Magina S, et al. Portuguese position paper on the use of biosimilars in psoriasis. Acta Med Port. 2016;29:574–7. https://doi.org/10.20344/amp.8118.

Article  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009. https://doi.org/10.1136/bmj.b2700.

Article  Google Scholar 

Hillard T, Baber R. Peer review: the cornerstone of scientific publishing integrity. Climacteric. 2021;24(2):107–8. https://doi.org/10.1080/13697137.2021.1882140.

Article  PubMed  Google Scholar 

Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):1–11. https://doi.org/10.1186/s40779-020-00238-8.

Article  Google Scholar 

de Boeck K, Castellani C, Elborn JS. Medical consensus, guidelines, and position papers: a policy for the ECFS. J Cyst Fibros Eur Cystic Fibrosis Soc. 2014;13:495–8. https://doi.org/10.1016/j.jcf.2014.06.012.

Article  Google Scholar 

EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed on 14 Sep 2022

Ruiz S. Biosimilars in the EU. Biosimilar Drug Prod Dev. 2017. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed on 15 Sep 2022

Callaghan JO, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019. https://doi.org/10.1007/s00228-018-2542-1.

Article  Google Scholar 

Feagan BG. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020;37:4491–518. https://doi.org/10.1007/s12325-020-01472-1.

Article  PubMed  PubMed Central  Google Scholar 

Afzali A, Furtner D, Melsheimer R, Molloy PJ. The Automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38(5):2077–93. https://doi.org/10.1007/s12325-021-01688-9.

Article  PubMed  PubMed Central  Google Scholar 

Frazer MB, Bubalo J, Patel H, Siderov J, Cubilla M, De Lemos M, et al. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. J Oncol Pharm Pract. 2020. https://doi.org/10.1177/1078155219893441.

Article  PubMed  Google Scholar 

Gregory GP, Carrington C, Cheah CY, Hawkes EA, Irving IM, Siderov J, et al. A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia Pac J Clin Oncol. 2020;16:211–21. https://doi.org/10.1111/ajco.13337.

Article  PubMed  Google Scholar 

Joshi GP, Benzon HT, Gan TJ, Vetter TR. Consistent definitions of clinical practice guidelines, consensus statements, position statements, and practice alerts. Anesth Analg. 2019;129:1767–70. https://doi.org/10.1213/ane.0000000000004236.

Article  PubMed  Google Scholar 

Azevedo VF, de Souza Meirelles E, Kochen JAL, Medeiros AC, Miszputen SJ, Teixeira FV, et al. Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease-Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmun Rev. 2015;14:769–73. https://doi.org/10.1016/j.autrev.2015.04.014.

Article  CAS  PubMed  Google Scholar 

Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, et al. AACE/ACE position statement on the use of follow-on biologics and biosimilars for endocrine diseases. Endocr Pract. 2017;23:1345–9. https://doi.org/10.4158/EP-2017-0052.

Article  PubMed  Google Scholar 

Jayagopal V, Drummond R, Nagi D. Association of British Clinical Diabetologists (ABCD) position statement on the use of biosimilar insulin. Br J Diabetes. 2018;18:171–4. https://doi.org/10.15277/bjd.2018.190.

Article  Google Scholar 

Burri E, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, et al. Swiss position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly. 2019;149: w20148.

CAS  PubMed  Google Scholar 

Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol. 2013;27:567–71. https://doi.org/10.4414/smw.2019.20148.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, Joaquín Hinojosa TT. Joint position statement by “Sociedad Española de Patología Digestiva”(Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología”(Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013;105(1):37–43. https://doi.org/10.4321/s1130-01082013000100006.

Article  PubMed  Google Scholar 

Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2019;51:632–9. https://doi.org/10.1016/j.dld.2019.02.004.

Article  PubMed  Google Scholar 

Mularczyk A, Gonciarz M, Bartnik W, Durlik M, Eder P, Ga̧siorowska A, et al. Biosimilar medicines—their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol. 2014;9:1–3. https://doi.org/10.5114/pg.2014.40842.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moayyedi P, Benchimol EI, Armstrong D, Yuan C, Fernandes A, Leontiadis GI. Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada position statement on biosimilars for the treatment of inflammatory bowel disease. J Can Assoc Gastroenterol. 2020;3:e1-9. https://doi.org/10.1093/jcag/gwz035.

Article  PubMed  Google Scholar 

Becker FG, Cleary M, Team RM, Holtermann H, The D, Agenda N, et al. Use of biosimilars in paediatric inflammatory bowel disease: an updated position statement of the paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019. https://doi.org/10.1097/MPG.0000000000002141.

Article  Google Scholar 

Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96:937–42. https://doi.org/10.3324/haematol.2011.041210.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gastl G, Geissler D, Geissler K, Lang A, Ludwig H, Müller M, et al. ASHO position paper on biosimilars. Memo. 2009;2:232–3. https://doi.org/10.1007/s12254-009-0162-2.

Article  Google Scholar 

De Castro NML, Matilla-Fernández MB, Fraga-Fuentes MD, Mangues-Bafalluy I, Asensi-Díez R, Cajaraville-Ordoñana G, et al. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines. Farm Hosp. 2018;42:180–3. https://doi.org/10.7399/fh.10973.

Article  Google Scholar 

Goncalves J, Matos de Brito P, Batista A, Feio J, Machado F, Aperta J, et al. Position paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies. J Clin Pharm Ther. 2017;42:239–43. https://doi.org/10.1111/jcpt.12477.

Article  CAS